71 related articles for article (PubMed ID: 31915999)
1. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
[TBL] [Abstract][Full Text] [Related]
2. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.
Ong SL; Garcea G; Thomasset SC; Mann CD; Neal CP; Abu Amara M; Dennison AR; Berry DP
J Gastrointest Surg; 2008 Jun; 12(6):1068-73. PubMed ID: 18043987
[TBL] [Abstract][Full Text] [Related]
3. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer.
Luo G; Xiao Z; Long J; Liu Z; Liu L; Liu C; Xu J; Ni Q; Yu X
J Gastrointest Surg; 2013 Dec; 17(12):2092-8. PubMed ID: 24146342
[TBL] [Abstract][Full Text] [Related]
4. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio.
Smith RA; Ghaneh P; Sutton R; Raraty M; Campbell F; Neoptolemos JP
J Gastrointest Surg; 2008 Aug; 12(8):1422-8. PubMed ID: 18543046
[TBL] [Abstract][Full Text] [Related]
6. The involvement of the hepatic artery is a risk factor for unresectability after neoadjuvant treatment in borderline pancreatic adenocarcinoma.
Secanella L; Busquets J; Peláez N; Sorribas M; Laquente B; Ruiz-Osuna S; Fabregat J
Surg Oncol; 2024 Feb; 52():102027. PubMed ID: 38113726
[TBL] [Abstract][Full Text] [Related]
7. Tumor Size Combined With CA-19 Level Improves Prediction of Survival of Patients With Pancreatic Adenocarcinoma Undergoing Perioperative Chemotherapy and Resection.
Said SA; Perlmutter BC; Wehrle CJ; Chang J; Hossain MS; Naffouje S; Joyce D; Simon R; Walsh RM; Augustin T
Am Surg; 2024 Jun; 90(6):1397-1405. PubMed ID: 38513242
[TBL] [Abstract][Full Text] [Related]
8. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy?
Turrini O; Schmidt CM; Moreno J; Parikh P; Matos JM; House MG; Zyromski NJ; Nakeeb A; Pitt HA; Lillemoe KD
J Gastrointest Surg; 2009 Oct; 13(10):1791-7. PubMed ID: 19459018
[TBL] [Abstract][Full Text] [Related]
9. Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study.
Yamada T; Minami T; Yamada M; Terauchi Y
Endocr J; 2023 Nov; 70(11):1069-1075. PubMed ID: 37690842
[TBL] [Abstract][Full Text] [Related]
10. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.
Honda K; Katzke VA; Hüsing A; Okaya S; Shoji H; Onidani K; Olsen A; Tjønneland A; Overvad K; Weiderpass E; Vineis P; Muller D; Tsilidis K; Palli D; Pala V; Tumino R; Naccarati A; Panico S; Aleksandrova K; Boeing H; Bueno-de-Mesquita HB; Peeters PH; Trichopoulou A; Lagiou P; Khaw KT; Wareham N; Travis RC; Merino S; Duell EJ; Rodríguez-Barranco M; Chirlaque MD; Barricarte A; Rebours V; Boutron-Ruault MC; Romana Mancini F; Brennan P; Scelo G; Manjer J; Sund M; Öhlund D; Canzian F; Kaaks R
Int J Cancer; 2019 Apr; 144(8):1877-1887. PubMed ID: 30259989
[TBL] [Abstract][Full Text] [Related]
11. Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis.
Raza SS; Khan H; Hajibandeh S; Hajibandeh S; Bartlett D; Chatzizacharias N; Roberts K; Marudanayagam R; Sutcliffe RP
HPB (Oxford); 2024 May; 26(5):630-638. PubMed ID: 38383207
[TBL] [Abstract][Full Text] [Related]
12. Preoperative CA19‑9 level and dual time point FDG‑PET/CT as strong biological indicators of borderline resectability in pancreatic cancer: A retrospective study.
Kobayashi K; Einama T; Tsunenari T; Yonamine N; Takao M; Takihata Y; Tsujimoto H; Ueno H; Tamura K; Ishida J; Kishi Y
Oncol Lett; 2024 Jun; 27(6):279. PubMed ID: 38699663
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute.
Zhao Y; Wang C
J Gastrointest Surg; 2020 Apr; 24(4):855-865. PubMed ID: 30945087
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma.
Kang CY; Wang J; Axell-House D; Soni P; Chu ML; Chipitsyna G; Sarosiek K; Sendecki J; Hyslop T; Al-Zoubi M; Yeo CJ; Arafat HA
J Gastrointest Surg; 2014 Jan; 18(1):7-15. PubMed ID: 24002763
[TBL] [Abstract][Full Text] [Related]
15. High-throughput enrichment of portal venous circulating tumor cells for highly sensitive diagnosis of CA19-9-negative pancreatic cancer patients using inertial microfluidics.
Zhu Z; Zhang Y; Zhang W; Tang D; Zhang S; Wang L; Zou X; Ni Z; Zhang S; Lv Y; Xiang N
Biosens Bioelectron; 2024 Sep; 259():116411. PubMed ID: 38781696
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges.
Dbouk M; Abe T; Koi C; Ando Y; Saba H; Abou Diwan E; MacGregor-Das A; Blackford AL; Mocci E; Beierl K; Dbouk A; He J; Burkhart R; Lennon AM; Sokoll L; Canto MI; Eshleman JR; Goggins M
Clin Cancer Res; 2023 Oct; 29(20):4178-4185. PubMed ID: 37566230
[TBL] [Abstract][Full Text] [Related]
17. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers.
Boyd LNC; Ali M; Comandatore A; Garajova I; Kam L; Puik JR; Fraga Rodrigues SM; Meijer LL; Le Large TYS; Besselink MG; Morelli L; Frampton A; van Laarhoven HWM; Giovannetti E; Kazemier G
JAMA Netw Open; 2023 Aug; 6(8):e2331197. PubMed ID: 37639271
[TBL] [Abstract][Full Text] [Related]
18. Preoperative CA19.9 level predicts lymph node metastasis in resectable adenocarcinoma of the head of the pancreas: A further plea for biological resectability criteria.
Coppola A; La Vaccara V; Farolfi T; Asbun HJ; Boggi U; Conlon K; Edwin B; Ferrone C; Jonas E; Kokudo N; Perez EM; Satoi S; Sparrelid E; Stauffer J; Zerbi A; Takemura N; Lai Q; Almerey T; Bernon M; Cammarata R; Djoumi Y; Gallagher T; Ghorbani P; Ginesini M; Hashimoto D; Kauffmann EF; Kleive D; Lluís N; González RM; Napoli N; Nappo G; Nebbia M; Ricchitelli S; Sahakyan MA; Yamamoto T; Coppola R; Caputo D
Int J Surg; 2023 Sep; ():. PubMed ID: 37738016
[TBL] [Abstract][Full Text] [Related]
19. Indications for staging laparoscopy in pancreatic cancer.
De Rosa A; Cameron IC; Gomez D
HPB (Oxford); 2016 Jan; 18(1):13-20. PubMed ID: 26776846
[TBL] [Abstract][Full Text] [Related]
20. The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program.
Levink IJM; Jaarsma SC; Koopmann BDM; van Riet PA; Overbeek KA; Meziani J; Sprij MLJA; Casadei R; Ingaldi C; Polkowski M; Engels MML; van der Waaij LA; Carrara S; Pando E; Vornhülz M; Honkoop P; Schoon EJ; Laukkarinen J; Bergmann JF; Rossi G; van Vilsteren FGI; van Berkel AM; Tabone T; Schwartz MP; Tan ACITL; van Hooft JE; Quispel R; van Soest E; Czacko L; Bruno MJ; Cahen DL;
United European Gastroenterol J; 2023 Sep; 11(7):601-611. PubMed ID: 37435855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
